Otsuka America Pharmaceutical, Inc. (OAPI) is all about people. It is the people of OAPI who make this an exciting and fulfilling environment — one which fosters an atmosphere of creativity and opportunity. And it is people to whom we are dedicated: patients who use our products, healthcare professionals who treat these patients, residents of our community, and colleagues with whom we serve.
As a company, we recognize the challenges and opportunities to be successful in an ever-evolving healthcare environment. OAPI has established a solid reputation for providing quality products, engaging well-trained professionals, and contributing to an industry that is undergoing significant and rapid changes. We have brought together a diverse group of highly-skilled individuals who have commercialized PLETAL® (cilostazol) Tablets1 and ABILIFY® (aripiprazole) Tablets2 and have developed strong collaborations with Bristol-Myers Squibb Co., which co-develops and co-promotes ABILIFY, and other companies such as Santarus, Inc. with whom OAPI co-promotes ZEGERID® (omeprazole) Powder for Oral Suspension3. We have also positioned ourselves for the commercialization of several other important products. It is an exciting time for us as an organization because we know that our business is growing, we have tremendous potential, and patients will benefit from our success.
With business expertise, a devotion to science and a passion for improving the quality of human life, Otsuka is becoming a major contributor to the pharmaceutical industry and setting standards to which others aspire.
